Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27Kip1 in the cyclin E–cdk2 complexes


Numerous studies have demonstrated the anticancer activity of the tomato carotenoid, lycopene. However, the molecular mechanism of this action remains unknown. Lycopene inhibition of human breast and endometrial cancer cell growth is associated with inhibition of cell cycle progression at the G1 phase. In this study we determined the lycopene-mediated changes in the cell cycle machinery. Cells synchronized in the G1 phase by serum deprivation were treated with lycopene or vehicle and restimulated with 5% serum. Lycopene treatment decreased serum-induced phosphorylation of the retinoblastoma protein and related pocket proteins. This effect was associated with reduced cyclin-dependent kinase (cdk4 and cdk2) activities with no alterations in CDK protein levels. Lycopene caused a decrease in cyclin D1 and D3 levels whereas cyclin E levels did not change. The CDK inhibitor p21Cip1/Waf1 abundance was reduced while p27Kip1 levels were unaltered in comparison to control cells. Serum stimulation of control cells resulted in reduction in the p27 content in the cyclin E–cdk2 complex and its accumulation in the cyclin D1–cdk4 complex. This change in distribution was largely prevented by lycopene treatment. These results suggest that lycopene inhibits cell cycle progression via reduction of the cyclin D level and retention of p27 in cyclin E–cdk2, thus leading to inhibition of G1 CDK activities.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7


  • Amir H, Karas M, Giat J, Danilenko M, Levy R, Yermiahu T, Levy J, Sharoni Y . 1999 Nutr. Cancer 33: 105–112

  • Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA, Sutherland RL . 1993 Oncogene 8: 2127–2133

  • Cheng M, Oliver P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ . 1999 EMBO J 18: 1571–1583

  • Countryman C, Bankson D, Collins S, Man B, Lin W . 1991 Clin. Chem. 37: 1056

  • Giovannucci E . 1999 J. Natl. Canc. Inst. 91: 317–331

  • Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC . 1995 J. Natl. Canc. Inst. 87: 1767–1776

  • Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M . 1998 Lancet 351: 1397–1399

  • Hiyama H, Iavarone A, Reeves SA . 1998 Oncogene 16: 1513–1523

  • Jeoung DI, Tang B, Sonenberg M . 1995 J. Biol. Chem. 270: 18367–18373

  • Karas M, Amir H, Fishman D, Danilenko M, Segal S, Nahum A, Koifmann A, Giat Y, Levy J, Sharoni Y . 2000 Nutr. Cancer 36: 101–111

  • Kim DJ, Takasuka N, Kim JM, Sekine K, Ota T, Asamoto M, Murakoshi M, Nishino H, Nir Z, Tsuda H . 1997 Cancer Lett. 120: 15–22

  • Kobayashi T, Itjima K, Mitamura T, Torilzuka K, Cyong J, Nagasawa H . 1996 Anticancer Drugs 7: 195–198

  • LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E . 1997 Genes Dev. 11: 847–862

  • Levy J, Bosin E, Feldman B, Giat Y, Miinster A, Danilenko M, Sharoni Y . 1995 Nutr. Cancer 24: 257–267

  • Liu Y, Martindale JL, Gorospe M, Holbrook NJ . 1996 Cancer Res 56: 31–35

  • Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ . 1999 J. Natl. Cancer Inst. 91: 620–625

  • Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, Jacks T . 1995 Genes Dev. 9: 935–944

  • Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO . 1997 Br J Cancer 76: 1115–1118

  • Mazars P, Barboule N, Baldin V, Vidal S, Ducommun B, Valette A . 1995 FEBS Lett 362: 295–300

  • Michaud DS, Feskanich D, Rimm EB, Colditz GA, Speizer FE, Willett WC, Giovannucci E . 2000 Am. J. Clin. Nutr. 72: 990–997

  • Musgrove EA, Swarbrick A, Lee CS, Cornish AL, Sutherland RL . 1998 Mol. Cell. Biol. 18: 1812–1825

  • Nagasawa H, Mitamura T, Sakamoto S, Yamamoto K . 1995 Anticancer Res 15: 1173–1178

  • Narisawa T, Fukaura Y, Hasebe M, Ito M, Aizawa R, Murakoshi M, Uemura S, Khachik F, Nishino H . 1996 Cancer Lett 107: 137–142

  • Planas Silva MD, Weinberg RA . 1997 Mol. Cell. Biol. 17: 4059–4069

  • Sharoni Y, Giron E, Rise M, Levy J . 1997 Cancer Detect Prevent 21: 118–123

  • Sherr CJ . 1995 Trends Biochem. Sci. 20: 187–190

  • Sherr CJ . 1996 Science 274: 1672–1677

  • Sherr CJ, Roberts JM . 1995 Genes Dev. 9: 1149–1163

  • Sweeney KJ, Musgrove EA, Watts CK, Sutherland RL . 1996 Cancer Treat Res. 83: 141–170

  • Tabibzadeh S, Kaffka KL, Kilian PL, Satyaswaroop PG . 1990 In Vitro Cell Dev. Biol. 26: 1173–1179

  • Teixeira C, Pratt MAC . 1997 Mol. Endocrinol 11: 1191–1202

  • Wang C -J, Lin J -K . 1989 Proc. Natl. Sci. Counc. B ROC 13: 176–183

  • Wang CJ, Chou MY, Lin JK . 1989 Cancer Letters 48: 135–142

  • Wang QM, Jones JB, Studzinski GP . 1996 Cancer Res. 56: 264–267

  • Watts CK, Brady A, Sarcevic B, deFazio A, Musgrove EA, Sutherland RL . 1995 Mol. Endocrinol. 9: 1804–1813

  • Watts CK, Sweeney KJ, Warlters A, Musgrove EA, Sutherland RL . 1994 Breast Cancer Res. Treat. 31: 95–105

  • Weinstat Saslow D, Merino MJ, Manrow RE, Lawrence JA, Bluth RF, Wittenbel KD, Simpson JF, Page DL, Steeg PS . 1995 Nat. Med. 1: 1257–1260

  • Zhang H, Hannon GJ, Beach D . 1994 Genes Dev. 8: 1750–1758

  • Zhang SM, Tang GW, Russell RM, Mayzel KA, Stampfer MJ, Willett WC, Hunter DJ . 1997 Am. J. Clin. Nutr. 66: 626–632

  • Zhou Q, Stetler Stevenson M, Steeg PS . 1997 Oncogene 15: 107–115

Download references


We thank Prof Robert L Sutherland, Dr Elizabeth A Musgrove, Alex Swarbrick and Angela Lei (Garvan Institute of Medical Research, Sydney) for the many helpful discussions and the technical support. We thank Dr Zohar Nir, LycoRed Natural Products Industries, Beer Sheva, Israel for donating purified lycopene. The studies were supported in part by the Israel Science Foundation founded by the Israel Academy of Science and Humanities; by LycoRed Natural Products Industries, Beer-Sheva, Israel; and by the S Daniel Abraham International Center for Health and Nutrition, Ben-Gurion University of the Negev.

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Cite this article

Nahum, A., Hirsch, K., Danilenko, M. et al. Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27Kip1 in the cyclin E–cdk2 complexes. Oncogene 20, 3428–3436 (2001).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • lycopene
  • breast cancer
  • endometrial cancer
  • cell cycle
  • cyclin D1
  • retinoblastoma
  • p27kip1

This article is cited by


Quick links